Pharmacy Groups tell HHS that Any Action on Rebate Rule Must Involve Fixing Pharmacy DIR Fees

WASHINGTON, DC (July 29, 2020) – As we continue to navigate this unprecedented time of uncertainty, NASP remains committed to best supporting your immediate needs while continuing to focus on the future.

Please click here to read the letter submitted to HHS by NASP and the country’s leading pharmacy groups stating that any action on a prescription drug rebate rule must address skyrocketing fees extracted by some pharmacy benefit managers on behalf of plan sponsors in Medicare Part D.